Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Conditions: NSCLC Stage IV; KRAS Gene Mutation; PD-1 Antibody; Chemotherapy Effect Interventions: Drug: SHR-1210; Drug: Apatinib; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Jiangsu HengRui Medicine Co., Ltd.; Shanghai Chest Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Study